Motif Bio PLC Annual Report and Accounts 2015 (8538V)

TIDMMTFB

RNS Number : 8538V

Motif Bio PLC

21 April 2016

Motif Bio plc

("Motif" or the "Company")

Annual Report and Accounts 2015 available on website

Motif Bio plc (AIM: MTFB) the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces that its Annual Report and Accounts 2015 is now available on its website:

http://www.motifbio.com/investors

For further information please contact:

 
 Motif Bio plc                                                        info@motifbio.com 
  Graham Lumsden (Chief Executive 
  Officer) 
  David Huang (Chief Medical Officer) 
 Zeus Capital Limited (NOMAD & 
  BROKER) 
  Phil Walker/Dan Bate 
  Dominic Wilson                                                    +44 (0)20 3829 5000 
 Northland Capital Partners Limited 
  (BROKER) 
  Patrick Claridge/ David Hignell 
  John Howes/ Rob Rees (Broking)                                    +44 (0)20 3861 6625 
 Walbrook PR Ltd. (FINANCIAL PR          +44 (0)20 7933 8780 or motifbio@walbrookpr.com 
  & IR)                                                        Mob: +44 (0)7980 541 893 
  Paul McManus                                                 Mob: +44 (0)7900 608 002 
  Mike Wort 
 
 MC Services AG (EUROPEAN IR) 
 Raimund Gabriel                                                     +49 (0)89 210 2280

Notes to Editors:

Motif is a clinical-stage biopharmaceutical company, specialising in the development of novel antibiotics that are designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria. Our lead product candidate, iclaprim, is being developed for the treatment of the most common and serious bacterial infections such as acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including those caused by resistant strains such as MRSA (methicillin-resistant Staphylococcus aureus). Two Phase III ABSSSI clinical trials are on track to be completed in 2017 and if approved, iclaprim could be ready for commercialization in 2018. The Company is in discussions with pharmaceutical companies and universities to build a pipeline of innovative antibiotics targeting Gram-positive and Gram-negative bacteria. For additional information about Motif please visit www.motifbio.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

ACSLFFELSIIIFIR

(END) Dow Jones Newswires

April 21, 2016 02:00 ET (06:00 GMT)

Grafico Azioni Motif Bio (LSE:MTFB)
Storico
Da Giu 2024 a Lug 2024